A detailed history of Stephens Inc transactions in Exact Sciences Corp stock. As of the latest transaction made, Stephens Inc holds 3,041 shares of EXAS stock, worth $176,712. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,041
Holding current value
$176,712
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$42.43 - $70.83 $129,029 - $215,394
3,041 New
3,041 $207,000
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $143,504 - $215,211
3,041 New
3,041 $206,000
Q2 2022

Aug 03, 2022

SELL
$35.61 - $76.23 $108,290 - $231,815
-3,041 Closed
0 $0
Q4 2021

Mar 07, 2022

SELL
$72.5 - $100.68 $1,740 - $2,416
-24 Reduced 0.78%
3,041 $237,000
Q2 2021

Aug 12, 2021

SELL
$93.66 - $139.27 $8,148 - $12,116
-87 Reduced 2.76%
3,065 $381,000
Q1 2021

May 14, 2021

BUY
$116.57 - $155.01 $367,428 - $488,591
3,152 New
3,152 $415,000
Q1 2020

May 14, 2020

SELL
$37.9 - $104.44 $158,687 - $437,290
-4,187 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$77.66 - $99.74 $76,805 - $98,642
-989 Reduced 19.11%
4,187 $387,000
Q3 2019

Oct 18, 2019

BUY
$90.37 - $122.49 $121,909 - $165,239
1,349 Added 35.25%
5,176 $468,000
Q2 2019

Aug 01, 2019

BUY
$89.51 - $118.04 $127,730 - $168,443
1,427 Added 59.46%
3,827 $452,000
Q1 2019

May 03, 2019

SELL
$61.98 - $96.5 $142,368 - $221,660
-2,297 Reduced 48.9%
2,400 $208,000
Q4 2018

Feb 11, 2019

SELL
$56.04 - $82.66 $22,584 - $33,311
-403 Reduced 7.9%
4,697 $296,000
Q3 2018

Nov 14, 2018

BUY
$48.29 - $80.6 $246,279 - $411,060
5,100 New
5,100 $402,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Stephens Inc Portfolio

Follow Stephens Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.